Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 May;32(5):623–625. doi: 10.1128/aac.32.5.623

Comparison of dosages, intervals, and drugs in the prevention of Pneumocystis carinii pneumonia.

W T Hughes 1
PMCID: PMC172241  PMID: 3260765

Abstract

The efficacies of trimethoprim (TMP)-sulfamethoxazole (SMZ), TMP-dapsone, dapsone, and pentamidine were compared for the prevention of Pneumocystis carinii pneumonia in the corticosteroid-treated-rat model. While 11 (73%) of 15 untreated control animals had P. carinii pneumonia after 10 weeks of immunosuppression, none of the animals given 125 mg of dapsone per kg daily, weekly, biweekly, or monthly had evidence of infection. Of the 10 rats given a single dose of dapsone 23 and 50 days after immunosuppression was started, 5 (50%) had P. carinii pneumonia. When three drugs were given separately to groups of 10 rats in single doses biweekly, P. carinii pneumonia occurred in 40% of those treated with TMP-SMZ and in none of those treated with TMP-dapsone; although only 2 of those treated with pentamidine survived for evaluation, both had P. carinii pneumonia. The experiments showed that dapsone is highly effective in chemoprophylaxis for P. carinii pneumonia when given at monthly intervals or more frequently and that dapsone and TMP-dapsone are more effective than is TMP-SMZ when given at biweekly intervals. It seems reasonable to expect that biweekly doses of dapsone or TMP-dapsone would provide an effective and reasonably safe chemoprophylaxis regimen for patients at high risk for P. carinii pneumonia, and studies to test such a scheme are justifiable. Biweekly doses are preferred over monthly doses to allow for occasional inadvertent omission of doses expected from patients.

Full text

PDF
623

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edelson P. J., Metroka C. E., Friedman-Kien A. Dapsone, trimethoprim-sulfamethoxazole, and the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Dec;103(6 ):963–963. doi: 10.7326/0003-4819-103-6-963. [DOI] [PubMed] [Google Scholar]
  2. Gordin F. M., Simon G. L., Wofsy C. B., Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984 Apr;100(4):495–499. doi: 10.7326/0003-4819-100-4-495. [DOI] [PubMed] [Google Scholar]
  3. Hughes W. T. Five-year absence of Pneumocystis carinii pneumonitis in a pediatric oncology center. J Infect Dis. 1984 Aug;150(2):305–306. doi: 10.1093/infdis/150.2.305-a. [DOI] [PubMed] [Google Scholar]
  4. Hughes W. T., Kim H. K., Price R. A., Miller C. Attempts at prophylaxis for murine Pneumocystis carinii pneumonitis. Curr Ther Res Clin Exp. 1973 Aug;15(8):581–587. [PubMed] [Google Scholar]
  5. Hughes W. T., Kuhn S., Chaudhary S., Feldman S., Verzosa M., Aur R. J., Pratt C., George S. L. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977 Dec 29;297(26):1419–1426. doi: 10.1056/NEJM197712292972602. [DOI] [PubMed] [Google Scholar]
  6. Hughes W. T., Rivera G. K., Schell M. J., Thornton D., Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987 Jun 25;316(26):1627–1632. doi: 10.1056/NEJM198706253162604. [DOI] [PubMed] [Google Scholar]
  7. Hughes W. T., Smith B. L. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1984 Oct;26(4):436–440. doi: 10.1128/aac.26.4.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jaffe H. S., Abrams D. I., Ammann A. J., Lewis B. J., Golden J. A. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet. 1983 Nov 12;2(8359):1109–1111. doi: 10.1016/s0140-6736(83)90627-x. [DOI] [PubMed] [Google Scholar]
  9. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982 Mar-Apr;4(2):426–428. doi: 10.1093/clinids/4.2.426. [DOI] [PubMed] [Google Scholar]
  10. Leoung G. S., Mills J., Hopewell P. C., Hughes W., Wofsy C. Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Jul;105(1):45–48. doi: 10.7326/0003-4819-105-1-45. [DOI] [PubMed] [Google Scholar]
  11. Peters J. H., Gordon G. R., Ghoul D. C., Tolentino J. G., Walsh G. P., Levy L. The diposition of the antileprotic drug dapsone (DDS) in Philippine subjects. Am J Trop Med Hyg. 1972 Jul;21(4):450–457. doi: 10.4269/ajtmh.1972.21.450. [DOI] [PubMed] [Google Scholar]
  12. Peters J. H., Murray J. F., Jr, Gordon G. R., Gelber R. H. Dapsone in saliva and plasma of man. Pharmacology. 1981;22(3):162–171. doi: 10.1159/000137486. [DOI] [PubMed] [Google Scholar]
  13. Western K. A., Norman L., Kaufmann A. G. Failure of pentamidine isethionate to provide chemoprophylaxis against Pneumocytis carinii infection in rats. J Infect Dis. 1975 Mar;131(3):273–276. doi: 10.1093/infdis/131.3.273. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES